ARTV · Artiva Biotherapeutics, Inc.

📣 What ARTV Says Is Next

• second half of 2026 · “Artiva expects to initiate the registrational trial in the second half of 2026 and report primary efficacy data in the second half of 2028, with a potential BLA submission in 2029.”
  Company press release, May 8, 2026 · SEC filing
• in 2026 · “Artiva plans to initiate a Phase 3 registrational trial evaluating AlloNK in refractory RA in 2026.”
  Company press release, May 8, 2026 · SEC filing

Quoted word for word from the company's press releases filed with the SEC. Timing is the company's own guidance, not a BioRadar estimate.

🧪 Trial & FDA Catalysts

• Aug 2027 · Phase 1 · Active Trial · AB-101 in Combination With B-Cell Depleting mAb in Patients Who Failed Treatment for Class
  Registry primary completion date, not a results date
• Aug 2027 · Phase 1 · Recruiting · Phase 1 to Investigate the Safety, Tolerability, and Efficacy of GCC2005 in Patients With
  Registry primary completion date, not a results date
• Jan 2028 · Phase 2 · Recruiting · AlloNK®, an Allogeneic Non-genetically Modified, Cord Blood-derived NK Cell Therapy, in Co
  Registry primary completion date, not a results date

📊 Drug Pipeline

Also used in these trials (approved or third-party drugs, not ARTV's own candidates): Cyclophosphamide, Interleukin-2, Rituximab, Obinutuzumab.

Source: ClinicalTrials.gov trials sponsored by the company, one row per candidate at its most advanced registered trial. FDA approvals: Drugs@FDA. Wrong or missing drug? Report it

💰 Cash Runway & Dilution Risk

ARTV holds $349.4M in cash and short-term investments (as of Jun 30, 2026) and burns about $20.7M/quarter from operations, an estimated runway of 50.8 months at that rate (BioRadar estimate, not company guidance).

Dilution pressure: 30 · Moderate

• Cash runway 51 months
• ATM program on file since Aug 2026 +15
• Shelf registration (S-3, Aug 2026) +10
• Company says cash lasts into 2029 -15Based on our current operating plans, we expect our existing cash, cash equivalents and investments will be sufficient to fund our planned operating expenses and capital expenditure requirements into 2029. 10-Q, Aug 2026
• Share count +100% in a year +20

Recent financing filings on SEC EDGAR:

• Aug 6, 2026 · Shelf registration with ATM program, up to $100M · S-3
• May 8, 2026 · ATM program · 424B5
• Aug 6, 2025 · Shelf registration with ATM program, up to $12M · S-3
• Jul 22, 2024 · Underwritten offering, $167M · 424B4
• Jun 28, 2024 · S-1 registration · S-1

Source: SEC EDGAR (XBRL cash flow and financing filings). Dilution Watch: every company ranked → · Get an alert when ARTV files for a raise →

👥 Who Owns ARTV

Share count 48,890,121 (latest 10-Q/10-K). Insiders: each officer's, director's and 10% owner's latest Form 3, 4 or 5, direct and indirect shares; options are not counted. 5%+ holders: latest Schedule 13D or 13G of each holder above 5%. Institutions: the largest 13F holders (13F quarter ending 2026-06-30). Sources have different dates, so the split is approximate. Source: SEC EDGAR.

📈 Recent Insider Activity (Form 4)

Only open-market purchases (P) and sales (S) are trading decisions. Awards (A), option exercises (M) and tax withholding (F) are compensation mechanics. Source: SEC Form 4.